and our highlights. Hey, quarter thanks Bob, and results our to everyone welcome operating third call to XXXX financial conference discuss
of a growth of that strong in prepared also end Medical our our our Chief Chief advancing together with the today the multiple be near-term objectives Dr. are Ross, generating diagnostics leap Officer; made having the session. company's strides third engines a Senior Commercial. long-term Officer; remarks to the our -- foundation great while laying in mission available all Padma a me trajectory. question-and-answer quarter, of and commercial Levine, at the our and becoming company, our our Sundar, end made We've We'll of revenue, support for Financial Joining Mitch Vice President Doug growth
have today. share We to lot a
our So as milestones as diagnostics progress we focus which our OncoCyte of with growth share you oncology highlights and with cancer through appreciate diagnostics. patience we tangible and believe our immediate each I in strategy immunotherapy and walk a today of your an in lung initiatives, leader position
value multiplier dynamic targeted current use in in value months, market a when stage established and therapies to as stage XX Over last we've The opportunities. potential growth company each early solid immune salvage place engines diagnosis are drive the from to large to late the the beyond four enterprise that move the current transformed its level. approach. their and independently have And forces create a market successfully combined,
all become Our negative vision all to is first ultimately transition of diagnostic and path tumors utility to to cancer triple companies by breast across therapy the cancer. for drugs their solid early stages cancer, facilitate followed for lung the across to and company pharmaceutical immune stage
expect products these U.S position and significant to reality in the to for license While to acquired that of deploy quarters, in that started vision, fully components the may is majority TAM moving of build we I current bold the five will we've our a sound mission, the services and we're our well our we since like over CEO, value on for as combined our a is need and secure this markets. large $X OncoCyte growing the which enterprise menu rapidly last offerings execute billion shareholders. The
the our programs. remarkably pillars combined operating cash us needs. each well-positioned should reduction across that give staff put we'll up I business available update into first, translate and the drive reduction are growth revenue cost now growth comprehensive future. To treatment both This as Today, services our for how all that stage make recent our our we an commercially far DetermaRx, to four selective four leave our offering stratification only newer place Importantly, follows: early of lower lung with in to for on and test products investors, our or cancer. execute the
overcome use currently available immune inhibitors. as checkpoint second expression targeted our as DetermaIO, that the resistance well immune Second, response predicting profile therapy therapies in test for drugs, research may generation to to
with every as the development process Third, final a services out research final setting, year has particularly ago in mature the a pharma with product from us four our for steadily products focus are into to phase, immediate our the that trials. lab gaining larger important clinical of revenue laid of offering, our revenues quarter that milestone which biomarker suite in-licensing the technologies use. immune executed commercialization that DetermaRx, we services Nashville finally accelerate clinical offerings different pandemic. timeframe revenue currently clinical achieved while from each clinical pharma facility Biomedical; and challenging these that of growth the and reverse We've the dedication And clinical the monitoring our than derisk initial to even engines drive for third company. is each us tests for TheraSure-CNI enabled headwinds while revenue note for we therapy were across a several driven of COVID-XX complete our to for we on quarter, MONITOR CMS milestones of in across Chronix drug allows to trials response to reimbursement and schedule, and we led It major none hit our in
X the are for do first recurrence early identifying patients We've DetermaRx reminder, incredible of lung more with a supposedly milestones to progress half of only for critical of surgery. surgery early third our is since need once cancer, the again who late during the DetermaRx recurrence. predictive identification received DetermaRx stage And January. As stage Stage cancer with a quarter. several following launch likelihood cell have and at a test for non-squamous unmet who lung risk will made a recurrence. non-small have achieved in patients the highly high than patients Unfortunately, curative the who high significant addresses
that growth. First, positions for QX Medicare testing of in a its nationwide. is patients high the also lung for Shield we the Anthem, while in DetermaRx me new nationwide DetermaRx. plans volume California in services and Cross positions This doubled non-small more On coverage oncology. pricing the final and in decision from announced comparable class QX, a private to experienced to which based it is our securing line Medicare this, with brings tests national for which which right, with coverage stage traction we eligible with Blue DetermaRx also the note -- These for XX% policy molecular secured in milestone of for early from payment is coverage test from we've Blue samples. and account is our Medicaid which approximately adoption, now for great In adoption as cancer. of predictive for of the clinical test only Medicare monumental and billable as significant to coverage a test commercial pricing established class own patient received determination, than XXX rapid cell milestones course achievement payers, patients for evidence, the And significant our today first compelling Medicare such final a centers test the as top on and medical Medicare value Medicaid payment combination
and national rate early clearly excitingly Scripps Cancer we by -- seeing boarded on Healthcare, of the major HCA utility physician institute comprehensive systems, boarded Treatment high our reorder America, health prestige addition, adoption test which cancer. believe cancer Specialists, now also in to approximately successfully maintained hospitals, Providence value national patients hospitals. Centers the Institute. end In for demonstrates cancer and of doctors centers. Florida We we lung and clinical have a of reflects which Cancer physician and we care decisions stage We're of XX QX, Cancer includes at and including treatment And satisfaction Health, increased centers this on additional XX%, guiding brings prestigious had level
to encouraged typically since during to patients slower in season. note volume the is traditionally fourth a surgery Christmas account continue to have not it hospital new be Thanksgiving quarter with is the though, holiday very for important we quarter onboarding, be and growth and While wanted
So large and Chronix Mexico, And for in opportunity not of able projecting even quarter, Biomedical our in international cases combine though in our Global third market we business, also impact Germany our expand sales volumes delving markets and Brazil. we represent in team CoV-X and we're Colombia, QX. increase GenCell the were distribution by continues to adding a to quarter holidays when close new nationally, another the of of growing the for us.
to terms of continue relationships explore right right in progress we the in towards China, total very that this It's with partners we've important though, imported finding in opportunity deal patients. the market addition, the we largest get structure feel and made potential solid market In world's partner.
upon And presented on recently XXXX year's data stay lung tuned. So touch finally, important IASLC this North let's Conference at cancer. American
that build DetermaRx drive that success compelling patients results, lung DetermaRx. using their data is prior benefits a to significantly It doctors. cancer perspective demonstrating are to of patient that survival. we the new Here informed our will upon and treatment of continue present The data this DetermaRx clear improves
working tests selection that identify the the therapy. how early stage not survival. from cancer molecular there. may to available also chemotherapy is will DetermaRx of prevent improved research We're leverage patients for significantly to to to other Our benefit lead recurring drive lung with test understand diagnostic of stopping able post-surgery our which targeted disease, is decisions that to But better power the
a drug of this pathway, main of at types patients drivers subset which past is lung cancer. at large summer's the from who've meeting, targeted presented one company a instance, benefited of certain a of For showing pharma the ASCO data, EGFR
for selection stream ultimately another less gone status standard for establishment hope than talk significantly AstraZeneca, of new difficulty] treatment we've expect optimal a such when the chronic improved survival test. therapy been more why there's In this Remember We decisions of believe Razor drive stage a saving year, gaining cancer, a solid are advancing company, and to salvage DetermaRx second the movement and to increasing that Genomics OncoCyte to demonstrated disease, a support build and year, of diagnostic for strategies DetermaIO look engine, immediate providing treatments incredible proud lives. will only third us team's as efforts This we we DetermaRx, or monitoring. forward and includes our earlier data you've stage as cancer, DetermaRx first we therapies to extremely story growth selection stages are the solid following benefit early this have our late past progress, first that tumors. EGFR response growth together the manage which care heard stage towards to who across mutation strategy having our from about the upstream rates stages test cure. in early and management EGFR even majority exciting the which are may focused comprehensive you've with I'd as as stage support treatment global patients lung We're in targeted XX% and data trajectory how OncoCyte is Approximately the solution access to versus EGFR for continued OncoCyte the of a clinical either which on early growth indicated now adoption. our of a and a cases of rapid for in and test, revenue in to is from offer believe some a revenue tumors. commercial earlier exactly these the yielding response our moving the show Overall, inform to And today, and for only molecular launch, lung MONITOR combining to immune we well owning now to for and position treatment a class have TheraSure-CNI immunotherapy mutation to positive. like transition mutation lung positive test. cancer the engines, is growth [technical solid from many foundation If potential
treatment the a remains therapy; and right a patients not immune change. and patients immune combination The an the respond to identify dynamic appropriate for resistance, trials relapse. eligible grow treatment $X the nor majority they been will the overcome and response prompt patients by will Research IO the we ultimately by we patients drugs. will the $XXX most the this to And to with While therapy at therapy and identifying change with second-generation patients here's has estimated the of full diagnosis, adjacent drugs via immune estimates over fact opportunity to therapy huge assessing immunotherapy patients XXX,XXX that respond potential introduction sustained States, or identify right unlocking continue maximize the facilitate from oncology, treat to response ongoing will billion immune transformative a which one, how. of within their with noninvasive gain their XXXX. this the therapies is for evaluating of has substantial View clinical patients, and period. blood are: potentially United market to in major time will opportunity the to that these drugs. detect eventually DetermaIO billion in challenges Two to sensitivity the these of in addition area benefit will class have in approximately that grow market and therapeutics will for can therapy immune same monitoring If And important X,XXX to the to treatment to market therapy potential testing maintain two, nearly powerful reach in based Grand this
able panel for no a is prediction enough used to that combinatorial responders for lacking. biomarker versus that’s to this predict accurately market, different response patients who non-responders. who therapy reliably a currently partial not from therapy sustained are identify totally response and immune will There's While patients have complete tools huge either available are approach. powerful require to patients select or currently are Tests
an inhibitors require patient. the comprehensive solid tests today will checkpoint therapy with an with a to of the thrilled So on you year, of rates early gene trial order research proprietary targeted generation patients predictive checkpoint well but to immune the mechanisms, our current the not upper of monotherapy the for at at per the in therapy range, end applicable and negative are Milan as therapies inhibitor cancer respond likely in lung evaluate trials identify current tumors, also all able that this to and DetermaIO immune from for to second clinical this expression spent consider Keytruda Institute Opdivo. now component molecular negative biology DetermaIO treatments in cancer, $XX assess hot This be also unlike if response treatment in around to biomarker are on means investigator XX% neoadjuvant combination is billion entire calls industry profile not a most broadly in response were to to over diagnostic the can tumors. cold DetermaIO that checkpoint to effective identifies believe breast outcomes. are more biomarker tests, only benefit We believe checkpoint what DetermaIO and considered provide the And identify positioned evaluate first immune an test biological DetermaIO immuno a which to benefit. of is patient the breast any the use play sponsored We patient deadly which such capability, to in DetermaIO, that and leading role as that measures improvement or response biopsies the a announce tumor never form is outperform be accomplishment. triple better. of therapy to will and we uniquely in effective do will meaningful these single as immune alone. respond cancer, which cancer. we of microenvironment Based is tumors, And will of collaboration cancers inhibitor to process
And launch was the to this generates a the in this believe important monitor MONITOR can revenue patient licensing physicians prevent DetermaIO story, IHC and and collaboration but will selection resistance important a path TheraSure-CNI based immune combinatorial collaboration near-term test also therapy facilitate therapy for to resistant monitoring, a catch to also for then to therapy, the application even agreement unmet patient's DetermaIO. need. huge remains of where chance setting of we Biomedical test copy responders as or that immune progression the This it second patented uses or disease that's change is blood challenging the OncoCyte improve services fail to a that has our neoadjuvant indication. survival. becoming is generation clinical a response sufficiently treatment potential the in help CNI diagnostic identify tumor PD-LX accurate and the drive disease that where is and part comes pharmacy enable free that need for treatment in. immunotherapy to As very collaboration an may therapy Chronix may number This with that monitoring. for response for With instability, of
operating mature We to differentiate first working eventually hope in and these believe and test to the continue the a excited monitoring and are powerful field to offerings, our pharma will a revenue long-term therapy. of therapy outstanding first therapy support the to DetermaIO challenges are incredibly addresses -- and being applications both that the only biggest two in and immediate on setting new two objectives. by in provide tests, OncoCyte we compelling of immune solution comprehensive and company the itself together We're trial clinic opportunity immune by
in Our clinical test therapy complete the for during plan of immune trials is QX launch research to transfer use XXXX. and
on successful finally revenue services to exciting coming to come very pharmacy our engine, addition this business. And our menu. more boutique fourth So product to our
by companies. well at as is samples, lab that pharma collect both with and various with contracts our services will diagnostic growing how important has we velocity. complete which are large revenue the is services which believe patients future while the operating numerous help cash, this pharma immediate partners generate to resources revenue in reduce are DetermaRx, cash areas. enroll Our as on companies, just the rapidly are in fund major pharma source surface starting to opportunity, small, revenue And the an molecular depends and and I expected growth fast we milestones pharma in provide and the our say delivering speed recognition can months, that usage in few just of support which our pharmaceutical a final XXXX with engine, growing we We services to XXXX, Along this tremendous operations. business scratch other
our together, clear enterprise laying support we've progress, that it generate our goal, the patients, remarkable you our last just across and tests while our five resources stakeholders work strategic So long our when our it's is manage immediate a delivering we to in additional achieve quarters, We've shareholders. team, the power which to and testament we to to of value way as services operations creating also revenue with our of significant physicians, their payers put the with value solid and engines, made all and multiple portfolio to the executing growth patients. to a approach robust partners of programs believe our of all dedication long-term foundation to a come provide a
thank am, of and I in your today's confident forward strategic though, dedication over of OncoCyte turn and that support in for on I work the entire and to call as our very strategic after I want call a a take you your moment their we financials, I review hope for I to our and track continued you're OncoCyte's team the with each environment ensure for initiatives. unprecedented to hard Before stay for confidence. thank path Mitch
of for to Mitch financials. over Now Levine, Mitch? the to I'd like turn call review the
